Small-cap winners now need cash—and real growth

The pivot in small-cap investing was already visible by 2015 because the old default had been much simpler: prior to the mid-2010s, small-cap investing primarily used single-factor approaches such as size-based selection, value metrics, or momentum, without explicit screening for cash generation or balance-sheet strength. That baseline matters because it shows what changed—investors were no longer treating small-cap exposure itself, or a single style tilt, as sufficient for stock selection.

By 2015, at least one prominent small-cap strategy had moved to a rules-based screening framework that explicitly targeted cash-flow and earnings metrics rather than relying on size or valuation alone. Specifically, the Pacer US Small Cap Cash Cows index methodology employed a rules-based process focusing on projected free cash flow, projected earnings, and free-cash-flow yield to select small-cap companies, marking a clear shift toward systematic quality and cash-generation screens.

What stands out in these small-cap screens is not a blanket appetite for risk but a clear reward for companies that pair cash-generation flexibility with durable growth. StockStory’s positive case for BioMarin Pharmaceutical rested on exactly that mix: 14.5% annual revenue growth over the last two years, projected revenue growth of 26.5% for the next 12 months, and a free cash flow margin that expanded by 5.6 percentage points, giving management more room to invest or return capital rather than merely look statistically cheap. The same logic showed up elsewhere: Astec was highlighted for estimated revenue growth of 12.9% and operating margin improvement, while Oscar Health was labeled “One Small-Cap Stock to Buy” because its free cash flow margin jumped by 19.9 percentage points over the last five years, giving the company more resources to pursue growth.

The flip side is just as important: cash or valuation support alone is no longer enough when operating trends are weak. Mission Produce was flagged for a projected 17% sales decline, a 12% gross margin, and a revenue base of $1.34 billion that “puts it at a disadvantage,” while Goodyear was criticized because negative free cash flow, a 4.9% annual sales drop, and dilution undermined flexibility; DBX was also criticized because projected sales are flat. By contrast, Astec and Oscar Health were favored for rising margins, double-digit growth, and sharply improving free cash flow, while Columbus McKinnon was rejected for flat sales, margin erosion, and falling EPS, and GT was rejected for negative free cash flow.

By the first days of October, StockStory was making the split impossible to miss. Its cash-focused promotions repeatedly argued that balance-sheet strength alone was not enough: the Sept. 8 headline “2 Cash-Heavy Stocks to Target This Week and 1 That Underwhelm” paired “One Stock to Sell: Insteel (IIIN)” with buys Plexus and Paymentus, even though all three were net-cash names—IIIN at $21.38 million, PLXS at $38.6 million, and PAY at $368.9 million—showing investors were being told to separate cash-rich winners from cash-rich laggards rather than treat cash as a blanket buy signal.

The deciding line was operating quality. StockStory said Insteel’s “Muted 4.9% annual revenue growth over the last five years,” EPS declines of 6.6% annually, and shrinking returns on capital outweighed its cash, while Plexus won support on 8.1% annual revenue growth, 20.6% projected growth, and buyback-aided EPS gains; the same pattern appeared in early October when MongoDB, with $2.38 billion of net cash, was praised for 17.7% forecasted growth and strong margins, even as Amplitude—tagged in “Two Stocks to Sell” despite a “Net Cash Position: $130.8 million (8.4% of Market Cap)”—was criticized for “Persistent operating margin losses,” “Lacking free cash flow generation,” and a “Net revenue” shortfall, and as Privia Health and Capital One were also flagged despite large net-cash positions because of losses, weak free cash flow, or deteriorating returns.

The broader case for small-cap strength rests less on blanket size exposure than on a normalization inside the Russell 2000 itself. On Bloomberg Surveillance, Bank of America’s Jill Carey Hall said the index still has “about a third of the companies are nonprofitable” and that the “amount of stocks that don't have earnings is elevated,” but she tied that distortion to “two earnings recessions Covid and then the recent one that started in 2020-20” and “an IPO boom in 2021 that caused a lot of nonprofitable stocks to get added,” then argued conditions were setting up for higher-quality companies to reassert leadership. That emphasis on quality and cash generation also matches the kind of company-specific evidence investors have been rewarding elsewhere: “DCAI 的獲利品質是十年來最好的。營業利益率由 16% 拉到 40%，且增量的九成來自產品獲利而非一次性項目.”

That shift was already showing up in returns by July. In the How-To analysis, the speaker said “last year was a year where the non profitable components of the Russell 2000 had double the performance of the profitable components,” adding, “It was up 20% versus up 10%,” but that leadership was reversing as profitable stocks began catching up and then outperforming—evidence that recent small-cap performance has been supported by investors rewarding earnings power, cash generation and operating resilience rather than simply buying the asset class indiscriminately. The same preference for verifiable operating improvement is reflected in examples such as “Panther Lake 單位成本年初至今下降約 50%…製程良率是英特爾過去五年最大的失分點，本季是少數可驗證的正面證據.”